Quick answer
Orforglipron is not available in the UK as of June 2026 — it has no MHRA approval, so no GPhC-registered provider can supply it. No confirmed UK launch date has been published. NHS access would also require a NICE appraisal. While you wait, the Wegovy tablet is approved from £64/month — speak to your prescriber.
When will orforglipron be available in the UK?
Orforglipron — the oral GLP-1 weight loss tablet from Eli Lilly — has generated significant interest since its phase 3 trial results were published. This page tracks the regulatory milestones between today and a potential UK launch.
Current status: not available in the UK
As of June 2026, orforglipron has not received MHRA approval for use in the United Kingdom. No GPhC-registered UK pharmacy or online clinic is legally permitted to supply it. Any UK website currently offering orforglipron is operating outside of UK law.
The regulatory pathway to a UK launch
For orforglipron to become legally available in the UK, the following must occur in sequence:
- MHRA submission: Eli Lilly must submit a Marketing Authorisation Application to the MHRA with full trial data, manufacturing information and proposed labelling.
- MHRA review: Standard review timelines are 210 days, though expedited pathways exist for medicines addressing unmet clinical need.
- MHRA approval: If approved, a Marketing Authorisation is granted and the drug can be legally prescribed in the UK.
- Commercial launch: Eli Lilly decides when to launch commercially. NHS pricing negotiations with NICE may add further months before the drug is widely accessible.
- Provider listings: UK pharmacies and online clinics begin listing orforglipron for private prescription. This is the point at which it would appear on our tracker.
What we know about timing
UK approval has historically followed US FDA approval by six months to two or more years depending on the drug and the manufacturer’s commercial priority for the UK market. Eli Lilly has not published a confirmed MHRA submission date or UK launch timeline for orforglipron as of June 2026.
Will the NHS cover orforglipron?
NHS coverage would require a positive NICE appraisal and a commercial agreement between Eli Lilly and NHS England. Given the existing complex access landscape for GLP-1 drugs on the NHS, private prescription access via online clinics is likely to come first.
How to be first to know
We track all MHRA announcements and Eli Lilly statements relating to orforglipron. When a UK approval or launch date is confirmed, we will update this page immediately and send email alerts to subscribers.
Notify me when orforglipron is approved in the UK
The Wegovy tablet is available now
If you are looking for an oral GLP-1 weight loss tablet currently available in the UK, the Wegovy tablet (oral semaglutide) is available on a pre-order basis from five providers, starting from £64 per month. See our live provider tracker for current prices and availability.
Related pages
Frequently asked questions
When will orforglipron be available in the UK?
No confirmed date. It is not yet MHRA-approved as of June 2026. We alert subscribers the moment approval or a launch date is confirmed.
Can I buy orforglipron in the UK now?
No. No GPhC-registered UK provider can legally supply orforglipron yet. Any site offering it is operating outside UK law.
Will orforglipron be on the NHS?
Not initially. NHS coverage needs a positive NICE appraisal and an NHS England agreement; private prescription access via online clinics is likely to come first.
What oral option is available while I wait?
The Wegovy tablet (oral semaglutide) is approved and on pre-order from £64/month. It is a prescription-only medicine — speak to your prescriber.